{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:10:42Z","timestamp":1767985842135,"version":"3.49.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.drugalcdep.2009.04.012","type":"journal-article","created":{"date-parts":[[2009,6,3]],"date-time":"2009-06-03T04:23:13Z","timestamp":1244002993000},"page":"1-10","source":"Crossref","is-referenced-by-count":107,"title":["Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem\u00ae): Differences in characteristics and misuse"],"prefix":"10.1016","volume":"104","author":[{"given":"Lawrence P.","family":"Carter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Gorsline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2009.04.012_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/jcp.0b013e31815a2542","article-title":"Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users","volume":"27","author":"Abanades","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1196\/annals.1369.065","article-title":"Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics","volume":"1074","author":"Abanades","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.annemergmed.2005.10.012","article-title":"Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003","volume":"47","author":"Anderson","year":"2006","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0376-8716(02)00311-3","article-title":"Postmarketing surveillance of abuse liability of sibutramine","volume":"69","author":"Arfken","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib5","unstructured":"Australian Institute of Health and Welfare, 2008. 2007 National Drug Strategy Household Survey: first results. Drug Statistics Series number 20.Cat. no. PHE 98. Canberra: AIHW. <http:\/\/www.aihw.gov.au\/publications\/index.cfm\/title\/10579> (accessed 8.10.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/02791072.2007.10399870","article-title":"Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study","volume":"39","author":"Barker","year":"2007","journal-title":"J. Psychoactive Drugs."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/j.1360-0443.2003.00554.x","article-title":"The role of an international nightlife resort in the proliferation of recreational drugs","volume":"98","author":"Bellis","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0091270003262795","article-title":"The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients","volume":"44","author":"Borgen","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/15563650701754763","article-title":"2006 Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System","volume":"45","author":"Bronstein","year":"2007","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/15563650802559632","article-title":"2007 Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 25th Annual Report","volume":"46","author":"Bronstein","year":"2008","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0317167100119304","article-title":"The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate","volume":"6","author":"Broughton","year":"1979","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.5694\/j.1326-5377.2004.tb06295.x","article-title":"Fatalities associated with the use of \u03b3-hydroxybutyrate and it analogues in Australasia","volume":"181","author":"Caldicott","year":"2004","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/jpet.102.047860","article-title":"The role of GABAB receptors in the discriminative stimulus effects of \u03b3-hydroxybutyrate in rats: time course and antagonism studies","volume":"305","author":"Carter","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib14","unstructured":"Carter, L.P., Griffiths, R.R., Mintzer, M.Z., 2007. Psychomotor, subjective, and cognitive effects of GHB and triazolam in healthy volunteers. Presented at the 69th Annual Meeting of the College on Problems of Drug Dependence. <http:\/\/www.cpdd.vcu.edu\/Pages\/Meetings\/MeetProgAbSearchAll.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pharmthera.2008.10.003","article-title":"Behavioral analyses of GHB: receptor mechanisms","volume":"121","author":"Carter","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib16","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1038\/sj.npp.1301146","article-title":"Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB","volume":"31","author":"Carter","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib17","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1124\/jpet.104.077578","article-title":"Novel gamma-hydroxybutyric acid (GHB) analogs share some, but not all behavioral effects of GHB and GABAB receptor agonists","volume":"313","author":"Carter","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/jama.265.4.447","article-title":"Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate","volume":"265","author":"Centers for Disease Control","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib19","first-page":"380","article-title":"Acute poisoning from \u03b3-hydroxybutyrate in California","volume":"156","author":"Chin","year":"1992","journal-title":"West. J Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0196-0644(98)70230-6","article-title":"Clinical course of gamma-hydroxybutyrate overdose","volume":"31","author":"Chin","year":"1998","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jat\/28.6.481","article-title":"Suspected GHB overdoses in the emergency department","volume":"28","author":"Couper","year":"2004","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0736-4679(99)00163-8","article-title":"Severe gamma-hydroxybutyrate withdrawal: a case report and literature review","volume":"18","author":"Craig","year":"2000","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1081\/JA-200066777","article-title":"Recent trends in the use of \u201cclub drugs\u201d: an Australian review","volume":"40","author":"Degenhardt","year":"2005","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0376-8716(02)00017-0","article-title":"GHB use among Australians: characteristics, use patterns and associated harm","volume":"67","author":"Degenhardt","year":"2002","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1360-0443.2003.00265.x","article-title":"The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users","volume":"98","author":"Degenhardt","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.drugpo.2007.08.007","article-title":"The epidemiology of GHB and ketamine use in an Australian household survey","volume":"19","author":"Degenhardt","year":"2008","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5694\/j.1326-5377.2008.tb01851.x","article-title":"Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne","volume":"188","author":"Dietze","year":"2008","journal-title":"Victoria Med. J. Aust."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib28","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1471-4159.1978.tb10460.x","article-title":"Metabolism of \u03b3-hydroxy-[1-14C] butyrate by rat brain: relationship to the Krebs cycle and metabolic compartmentation of amino acids","volume":"30","author":"Doherty","year":"1978","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1191\/096032701666142043","article-title":"Near-fatal gamma-butyrolactone intoxication\u2014first report in the UK","volume":"20","author":"Dupont","year":"2001","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0735-6757(91)90050-T","article-title":"\u03b3-Hydroxybutyrate: a health-food product producing coma and seizurelike activity","volume":"9","author":"Dyer","year":"1991","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1067\/mem.2001.112985","article-title":"Gamma-hydroxybutyrate withdrawal syndrome","volume":"37","author":"Dyer","year":"2001","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jat\/23.3.141","article-title":"Prevalence of drugs used in cases of alleged sexual assault","volume":"23","author":"ElSohly","year":"1999","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib33","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, Annual report 2007: the state of the drugs problem in Europe. Luxembourg: Office for Official Publications of the European Communities. <http:\/\/www.emcdda.europa.eu\/html.cfm\/index44682EN.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib34","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, Annual report 2008: the state of the drugs problem in Europe. Luxembourg: Office for Official Publications of the European Communities. <http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_64227_EN_EMCDDA_AR08_en.pdf> (accessed 6.02.09.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1520\/JFS13816J","article-title":"Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication","volume":"40","author":"Ferrara","year":"1995","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib36","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1212\/01.wnl.0000188670.38576.bd","article-title":"A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor","volume":"65","author":"Frucht","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002018-200427050-00002","article-title":"The Xyrem risk management program","volume":"27","author":"Fuller","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1360-0443.1997.tb03640.x","article-title":"Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence","volume":"92","author":"Galloway","year":"1997","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000085551","article-title":"Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report","volume":"11","author":"Glasper","year":"2005","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00213-005-2165-y","article-title":"Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons","volume":"180","author":"Goodwin","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00213-006-0534-9","article-title":"Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons","volume":"189","author":"Goodwin","year":"2006","journal-title":"Psychopharmacology"},{"issue":"Suppl. 3","key":"10.1016\/j.drugalcdep.2009.04.012_bib42","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","article-title":"Principles of initial experimental drug abuse liability assessment in humans","volume":"70","author":"Griffiths","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"Suppl.","key":"10.1016\/j.drugalcdep.2009.04.012_bib43","first-page":"31","article-title":"Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds","volume":"66","author":"Griffiths","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib44","unstructured":"Hawaii Revised Statute, Chapter 329 \u2013 Uniformed Controlled Substances Act. <http:\/\/hawaii.gov\/dcca\/areas\/pvl\/main\/hrs\/> (accessed 1.10.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib45","unstructured":"Hillebrand, J., Olszewski, D., Sedefov, R., 2008. EMCDDA Thematic Papers\u2014GHB and its precursor GBL: an emerging trend case study. European Monitoring Centre for Drugs and Drug Addiction. <http:\/\/www.emcdda.europa.eu\/html.cfm\/index50526EN.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib46","unstructured":"Johnston, L.D., O\u2019Malley, P.M., Bachman, J.G., Schulenberg, J.E., 2008. Various stimulant drugs show continuing gradual declines among teens in 2008, most illicit drugs hold steady, University of Michigan News Service: Ann Arbor, MI. <http:\/\/monitoringthefuture.org\/> (accessed 23.01.09.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib47","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1556-4029.2007.00583.x","article-title":"An estimate of the proportion of drug-facilitation of sexual assault in four U.S. localities","volume":"52","author":"Juhascik","year":"2007","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/00952990701312316","article-title":"High-risk behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users","volume":"33","author":"Kim","year":"2007","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/10550490802138988","article-title":"Systematic assessment of gamma hydroxybutyrate (GHB) effects during and after acute intoxication","volume":"17","author":"Kim","year":"2008","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/15563650701263633","article-title":"High mortality rates among GHB abusers in Western Sweden","volume":"46","author":"Knudsen","year":"2008","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib51","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/15563650600907165","article-title":"2005 Annual Report of the American Association of Poison Control Centers\u2019 National Poisoning and Exposure Database","volume":"44","author":"Lai","year":"2006","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0379-0738(00)00426-6","article-title":"Effect of storage temperature on endogenous GHB levels in urine","volume":"15","author":"LeBeau","year":"2001","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib53","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.forsciint.2006.08.007","article-title":"Further evidence of in vitro production of gamma-hydroxybutyrate (GHB) in urine samples","volume":"169","author":"LeBeau","year":"2007","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/jat\/30.2.98","article-title":"A comprehensive study on the variations in urinary concentrations of endogenous gamma-hydroxybutyrate (GHB)","volume":"30","author":"LeBeau","year":"2006","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib55","first-page":"107","article-title":"Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium \u03b3-hydroxybutyrate and \u03b3-butyrolactone","volume":"22","author":"Lettieri","year":"1978","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1053\/ajem.2002.34955","article-title":"2001 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"20","author":"Litovitz","year":"2002","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib57","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0301-0082(96)00064-0","article-title":"The \u03b3-hydroxybutyrate signaling system in brain: organization and functional implications","volume":"51","author":"Maitre","year":"1997","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib58","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/jama.277.19.1505","article-title":"Coma-inducing drug GHB may be reclassified","volume":"277","author":"Marwick","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib59","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1553-2712.2002.tb02154.x","article-title":"Gamma hydroxybutyric acid (GHB) intoxication","volume":"9","author":"Mason","year":"2002","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib60","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1081\/JA-200066968","article-title":"Profiles of club drug users in treatment","volume":"40","author":"Maxwell","year":"2005","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/02791072.2001.10400479","article-title":"Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies","volume":"33","author":"McDaniel","year":"2001","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib62","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/105504901750532111","article-title":"Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal","volume":"10","author":"Miotto","year":"2001","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib63","unstructured":"National Drug Intelligence Center U.S. Department of Justice, 2008. National Drug Threat Assessment 2009. <http:\/\/www.usdoj.gov\/ndic\/pubs31\/31379\/index.htm> (accessed 23.01.09.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib64","unstructured":"Nevada Administrative Code, Chapter 453 \u2013 Controlled Substances. <http:\/\/www.leg.state.nv.us\/NAC\/NAC-453.html#NAC453Sec510> (accessed 1.10.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(00)00191-5","article-title":"GHB: a new and novel drug of abuse","volume":"63","author":"Nicholson","year":"2001","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib66","unstructured":"Office of Diversion Control, 2008. National Forensic Laboratory Information System: Year 2007 Annual Report. Washington, DC: U.S. Drug Enforcement Administration. http:\/\/www.deadiversion.usdoj.gov\/nflis\/index.html (accessed 6.02.09.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib67","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00265954","article-title":"Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers","volume":"45","author":"Palatini","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00139709-200423010-00003","article-title":"Gamma-butyrolactone and 1,4-buandiol: abused analogues of gamma-hydroxybutyrate","volume":"23","author":"Palmer","year":"2004","journal-title":"Toxicol. Rev."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib69","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2165\/00023210-200620120-00004","article-title":"Gamma-hydroxybutyrate\/sodium oxybate: neurobiology, and impact on sleep and wakefulness","volume":"20","author":"Pardi","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib70","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1192\/bjp.177.2.181","article-title":"In-patient detoxification after GHB dependence","volume":"177","author":"Price","year":"2000","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.24142","article-title":"Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"60","author":"Russell","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib72","first-page":"222","article-title":"The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy","volume":"46","author":"Scharf","year":"1985","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib73","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/sleep\/21.5.507","article-title":"Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients","volume":"21","author":"Scharf","year":"1998","journal-title":"Sleep"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib74","first-page":"425","article-title":"Involvement of drugs in sexual assault","volume":"45","author":"Slaughter","year":"2000","journal-title":"J. Reprod. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib75","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1742-6723.2005.00736.x","article-title":"Survival of massive gamma-hydroxybutyrate\/1,4-butanediol overdose","volume":"17","author":"Strickland","year":"2005","journal-title":"Emerg. Med. Australas."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib76","unstructured":"Strom, K.J., Wong, L., Fornnarino, L., Eicheldinder, C., Bethke, A., Ancheta, J., Rachal, V., 2003. The National Forensic Laboratory Information System: 2002 Annual Report. Washington, DC: U.S. Drug Enforcement Administration. <http:\/\/www.deadiversion.usdoj.gov\/nflis\/index.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib77","unstructured":"Strom, K.J., Wong, L., Fornnarino, L., Eicheldinger, C., Bethke, A., Ancheta, J., Rachal, V., 2004. The National Forensic Laboratory Information System: 2003 Annual Report. Washington, DC: U.S. Drug Enforcement Administration. <http:\/\/www.deadiversion.usdoj.gov\/nflis\/index.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib78","unstructured":"Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2008a. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-30, DHHS Publication No. (SMA) 08-4339, Rockville, MD. <http:\/\/dawninfo.samhsa.gov\/pubs\/edpubs\/default.asp> (accessed 6.02.09.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib79","unstructured":"Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2008b. Results from the 2007 National Survey on Drug Use and Health: National Findings. NSDUH Series H-34, DHHS Publication No. (SMA) 08-4343, Rockville, MD. <http:\/\/oas.samhsa.gov\/nsduh\/2k7nsduh\/2k7Results.pdf> (accessed 6.02.09.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib80","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.drugalcdep.2007.07.009","article-title":"Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB)","volume":"92","author":"Sumnall","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib81","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00139709-200423010-00005","article-title":"The gamma-hydroxybutyrate withdrawal syndrome","volume":"23","author":"Tarabar","year":"2004","journal-title":"Toxicol. Rev."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib82","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.jcp.0000237944.57893.28","article-title":"Gamma-hydroxybutyrate and ethanol effects and interactions in humans","volume":"26","author":"Thai","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib83","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.clpt.6100037","article-title":"Clinical pharmacology of 1,4-butandiol and gamma-hydroxybutyrate after oral 1,4-butanediol administration in healthy volunteers","volume":"81","author":"Thai","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib84","unstructured":"The National Forensic Laboratory Information System, 2001. Year 2000 Annual Report. U.S. Drug Enforcement Administration, Office of Diversion Control. Washington, D.C. <http:\/\/www.deadiversion.usdoj.gov\/nflis\/index.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib85","unstructured":"The National Forensic Laboratory Information System, 2002. Year 2001 Annual Report. U.S. Drug Enforcement Administration, Office of Diversion Control. Washington, D.C. <http:\/\/www.deadiversion.usdoj.gov\/nflis\/index.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib86","unstructured":"U.S. Controlled Substances Act. Title 21, U.S.C. 802(34). http:\/\/www.deadiversion.usdoj.gov\/21cfr\/21usc\/802.htm#34 (accessed 4.09.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib87","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1081\/CLT-120019128","article-title":"The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms","volume":"41","author":"U.S. Xyrem Multi-Center Study Group","year":"2003","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib88","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/15563650701365818","article-title":"Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series","volume":"45","author":"Van Sassenbroeck","year":"2007","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib89","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/emj.2002.002402","article-title":"Gamma hydroxybutirate use for sexual assault","volume":"21","author":"Varela","year":"2004","journal-title":"Emerg. Med. J."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib90","unstructured":"Wang, Y.G., Swick, T.J., Carter, L.P., Thorpy, M.J., Benowitz, N.L. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem\u00ae): abuse, misuse, dependence, and diversion. J. Clin. Sleep Med, in press."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib91","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ajem.2005.05.001","article-title":"2004 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"23","author":"Watson","year":"2005","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ajem.2004.06.001","article-title":"2003 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"22","author":"Watson","year":"2004","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib93","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0735-6757(03)00088-3","article-title":"2002 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"21","author":"Watson","year":"2003","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib94","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/157488606775252647","article-title":"The clinical development of \u03b3-hydroxybutyrate (GHB)","volume":"1","author":"Wedin","year":"2006","journal-title":"Curr. Drug Safety"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib95","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00213-004-2079-0","article-title":"Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons","volume":"179","author":"Weerts","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib96","unstructured":"Weimer, B.J., Peters, D., Sannerud, C., Eicheldinger, C., Ancheta, J., Strom, K., Rachal, V., 2007. The National Forensic Laboratory Information System: 2006 Annual Report. Washington, DC: U.S. Drug Enforcement Administration. <http:\/\/www.deadiversion.usdoj.gov\/nflis\/index.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib97","unstructured":"Weimer, B.J., Wong, L., Sannerud, C., Eicheldinger, C., Ancheta, J., Strom, K., Rachal, V., 2006. The National Forensic Laboratory Information System: 2005 Annual Report. Washington DC: U.S. Drug Enforcement Administration. <http:\/\/www.deadiversion.usdoj.gov\/nflis\/index.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib98","unstructured":"Weimer, B.J., Wong, L., Strom, K., Forti, A., Eicheldinger, C., Bethke, A., Ancheta, J., Rachal, V., 2004. The National Forensic Laboratory Information System: Year 2004 Annual Report. Washington, DC: U.S. Drug Enforcement Administration. <http:\/\/www.deadiversion.usdoj.gov\/nflis\/index.html> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib99","first-page":"187","article-title":"Gamma-hydroxybutyric acid poisoning","volume":"168","author":"Williams","year":"1998","journal-title":"West. J. Med."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1542\/peds.106.4.829","article-title":"Verve and Jolt: deadly new internet drugs","volume":"106","author":"Winickoff","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib101","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1017\/S1481803500010034","article-title":"Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review","volume":"10","author":"Wojtowicz","year":"2008","journal-title":"CJEM"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/qjmed\/hcm117","article-title":"Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD)","volume":"101","author":"Wood","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib103","unstructured":"Xyrem Prescribing Information, 2008. Jazz Pharmaceuticals, Inc. <http:\/\/www.xyrem.com\/prescribing-information.php> (accessed 17.07.08.)."},{"key":"10.1016\/j.drugalcdep.2009.04.012_bib104","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJM200101113440202","article-title":"Adverse events, including death, associated with the use of 1,4-butandiol","volume":"544","author":"Zvosec","year":"2001","journal-title":"New Engl. J. Med."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871609001537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871609001537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T22:48:37Z","timestamp":1589842117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871609001537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":104,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0376871609001537"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2009.04.012","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}